An interesting week for the healthcare sector as Amazon shakes up regular pharmacies with its entrance into healthcare. Furthermore, Italian researchers publish results on study in longevity and claim there might be no limit to aging. Google and AbbVie increase their bet in aging research, AstraZeneca and Merck’s Lynparza reports delayed progression of ovarian cancer and Pfizer’s Ibrance fails at extending survival in some breast cancer patients.
In Mexico, UNAM reported that women are not performing mammograms as often as they should and an NGO decried the growing rate of childhood pregnancy.
Mexico Health Review spoke with Grupo Neolpharma’s Efrén Ocampo on the company’s R&D efforts in nanotechnology and biotechnology.
Now, jump into last week’s highlights:
Ipas Mexico presented its study “Sexual Violence and Teenage Pregnancy in Mexico: a Public Healthcare and Human Rights Problem,” shining a light on the growing pregnancy rate of girls between 10 and 14 years old.
UNAM reported that only two out of every 10 Mexican women seek mammograms at the recommended rate, risking late detection of breast cancer.
AstraZeneca and Merck report significant delayed progression of ovarian cancer with after the use of Lynparza in a phase III clinical trial.
Pfizer’s Ibrance, a breast cancer drug, failed at extending survival in certain patients in a late-stage trial. On the other hand, the pharmaceutical’s smoking-cessation drug Chantix approached blockbuster designation.
Google and AbbVie’s Calico perform a joint investment of US$1 billion for anti-aging research. Both companies had previously backed Calico with a joint US$1.5 billion.
Researchers from Italy publish controversial study questioning the limits of longevity. After studying the survival probabilities of almost 4,000 individuals over 105 years of age, researchers claimed that after that age, individuals reach a mortality plateau.